Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D H Miller

Showing results (431-440 of 768) with videos related to

Pageof 77
Sort By:
Neurology|June 10, 2010
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypesN De Stefano, A Giorgio, M Battaglini, et al.
Journal of Neurology|December 25, 2012
Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosisH Vrenken, M Jenkinson, M A Horsfield, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 23, 2000
Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging studyD J Werring, E T Bullmore, A T Toosy, et al.
Brain : a Journal of Neurology|October 26, 2000
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activityR B Banati, J Newcombe, R N Gunn, et al.
European Radiology|May 6, 2009
A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndromeT Korteweg, M Tintore, B M J Uitdehaag, et al.
Neurology|August 24, 2005
Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI dataJ Sastre-Garriga, G T Ingle, M Rovaris, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Differential diagnosis of suspected multiple sclerosis: a consensus approachD H Miller, B G Weinshenker, M Filippi, et al.
Neurology|April 25, 2007
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSD H Miller, D Soon, K T Fernando, et al.
Neurology|November 7, 2008
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyO Stüve, P D Cravens, E M Frohman, et al.
Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.
Pageof 77

Showing results (431-440 of 768) with videos related to

Sort By:
Pageof 77
Neurology|June 10, 2010
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypesN De Stefano, A Giorgio, M Battaglini, et al.
Journal of Neurology|December 25, 2012
Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosisH Vrenken, M Jenkinson, M A Horsfield, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 23, 2000
Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging studyD J Werring, E T Bullmore, A T Toosy, et al.
Brain : a Journal of Neurology|October 26, 2000
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activityR B Banati, J Newcombe, R N Gunn, et al.
European Radiology|May 6, 2009
A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndromeT Korteweg, M Tintore, B M J Uitdehaag, et al.
Neurology|August 24, 2005
Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI dataJ Sastre-Garriga, G T Ingle, M Rovaris, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Differential diagnosis of suspected multiple sclerosis: a consensus approachD H Miller, B G Weinshenker, M Filippi, et al.
Neurology|April 25, 2007
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSD H Miller, D Soon, K T Fernando, et al.
Neurology|November 7, 2008
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyO Stüve, P D Cravens, E M Frohman, et al.
Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.
Pageof 77